SLC5A2 and Hyperglycemia: The SGLT2 inhibitor was successful in normalizing the systolic blood pressure of diabetic mice, in addition to the hyperglycemia-induced rise in renal angiotensinogen mRNA and urine 8-isoprostane levels.